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A B S T R A C T 
Objective: To investigate the clinical efficacy and 
safety of irreversible electroporation for ablation of 
liver tumour in humans.
Data sources: The PubMed and MEDLINE databases 
were systematically searched.
Study selection: Clinical research published in 
English in the last 10 years until October 2013 
that address clinical issues related to irreversible 
electroporation of human liver tumours were 
selected. “Liver tumour”, “local ablative therapy”, 
and “irreversible electroporation” were used as the 
search terms.
Data extraction and synthesis: The data extracted 
for this review was analysed by the authors, with 
a focus on the clinical efficacy and the safety of 
irreversible electroporation. The complete response 
rates look promising, ranging from 72% to 100%, 
except in one study in a subgroup of liver tumours 
in which the complete response rate was only 50% 
that was likely due to the inclusion of larger-size 
tumours. In one study, the local recurrence rate at 
12 months was approximately 40%. As for the safety 
of irreversible electroporation, there were only a 
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Introduction
Local ablative therapies are frequently employed for 
the treatment of primary and secondary malignancies 
in the liver. Common choices include radiofrequency 
and microwave ablation. These treatment modalities, 
however, may cause thermal injury to major bile ducts 
within periductal tumours. In addition, the efficacy 
of thermal ablative therapy is often undermined by 
the heat sink effect, whereby the delivered thermal 
energy is dissipated via a continuous high blood flow 
in nearby major portal pedicles and hepatic veins. 
Recently, the use of irreversible electroporation 
(IRE) has been introduced into clinical practice. The 
aim of this article was to provide an updated review 
of the latest developments of this new technology in 
the management of liver tumours.
Methods
A search on the medical literature was performed to 
identify the relevant studies and reviews regarding 
the use of IRE as a treatment for primary liver 
neoplasm. Both PubMed and MEDLINE databases 
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were searched for clinical studies published in 
English in the last 10 years (until October 2013)
that involved the use of IRE for liver tumours. Key 
words used for the literature search were: “liver 
tumour”, “local ablative therapy”, and “irreversible 
electroporation”. 
Mechanism and history of 
electroporation
Electroporation utilises electrical fields to induce 
changes to plasma membrane permeability. More 
specifically, multiple rapid direct current electrical 
pulses are applied to the tissue of interest. These 
electrical pulses induce nano-scale pores within 
the phospholipid bilayer, thus changing cell 
permeability.1 There are two types: reversible 
electroporation (RE) and IRE.
 As the name suggests, tissues subjected to 
RE remain viable after the procedure. The lesser 
electrical strength and duration of the applied pulses 
during the procedure allow pores in the membrane 
to spontaneously seal by themselves. Researchers 
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few reported complications (cardiac arrhythmia, 
pneumothorax, and electrolyte disturbance) that 
were mostly transient and not serious. There was no 
reported mortality related to the use of irreversible 
electroporation.
Conclusion: Irreversible electroporation is a 
potentially effective liver tumour ablative therapy 
that gives rise to only mild and transient side-effects. 
Further studies with better patient selection criteria 
and longer follow-up are needed to clarify its role as 
a first-line liver tumour treatment modality.
  #  Yeung et al #
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醫治肝腫瘤的不可逆轉電穿孔技術的最新進展
楊思朗、鍾永賢、黃基定、黃彥淇、蘇智德、陳智仁
目的：探討針對人類肝腫瘤消融不可逆轉電穿孔技術的臨床療效和安
全性。
資料來源：有系統地搜查在PubMed和MEDLINE數據庫中的有關資
料。
研究選取：選取過去十年直至2013年10月前發表有關人類肝腫瘤不
可逆轉電穿孔技術的臨床研究的英文文獻。用以搜索文獻的關鍵詞 
為「肝腫瘤」（liver tumour）、「局部消融法」（local ablative 
therapy）和「不可逆轉的電穿孔術」（irreversible electroporation）。
資料提取及綜合：由作者分析選取的資料，重點針對不可逆轉電穿孔
技術的臨床療效和安全性。經不可逆轉電穿孔技術治理肝腫瘤的完全
緩解率介乎72%至100%，結果令人滿意。只有一項研究的其中一個
病人小組，可能由於腫瘤較大的關係，其完全緩解率只有50%。另一
項研究中，術後12個月的局部復發率約為40%。安全性方面，有關不
可逆轉電穿孔的併發症報導（心律失常、氣胸、電解質紊亂）只有少
數，但大多是短暫的，並不嚴重。沒有與使用不可逆轉電穿孔技術的
死亡報告。
結論：不可逆轉電穿孔是一種潛在有效的肝腫瘤消融治療技術，只會
產生輕微和短暫的副作用。須使用更佳的標準選擇合適病人和長期隨
訪作進一步研究。
exploited this unique effect of a transient increase 
in cell permeability to enable foreign materials 
that were previously deemed impermeable to pass 
through the phospholipid bilayer. A prominent 
example would be electrochemotherapy. Since 
the 1990s, multiple human clinical trials2-4 have 
shown that RE applied for this purpose enhances 
the delivery of chemotherapy (eg bleomycin) to the 
desired tissue (eg skin cancer, breast cancer).
 By contrast, IRE relies on delivering electrical 
pulses whose strength and/or duration exceeds the 
threshold of spontaneous cell membrane repair. The 
permanent permeability of the cell membrane that 
they induce disrupts the homeostasis of the cells, 
leading to cell death. Interestingly, this technique 
was largely ignored by the medical community until 
2005, when Davalos et al5 proved its theoretical basis 
via a mathematical analysis. This predicted that 
“irreversible electroporation can ablate substantial 
volumes of tissue, comparable to those achieved 
with other ablation techniques, without causing any 
detrimental thermal effects and without the need of 
adjuvant drugs.”5
 Rubinsky et al6 performed the first 
experimental IRE in 2007 by performing 35 ablations 
on 14 swine livers. Interestingly, all animals survived 
till the electrical pulse applications ceased, but 
reversible chemical paralysis was necessary to 
prevent unwanted muscular contractions during the 
procedure. Histologically there was haemorrhagic 
necrosis of the liver, but preservation of the vessels 
and bile ducts within the zones of ablation.7 
 Since then, many other animal studies have 
been performed in various organs and tissues, 
including liver, prostate, pancreas, small bowel, 
kidney, carotid artery, atrial appendages, and lung. 
The results were encouraging, in that IRE conferred 
three key advantages in all of these studies:
(1) It was effective in ablating tissues of interest, 
including tumours.
(2) It lacked the heat-sink effect. Traditional thermal 
ablation relied on tissue temperature reaching a 
certain threshold (60°C) in order to induce cell 
death. Cells near the large vessels were therefore 
prone to the continuously cooling effect from 
the flowing fluids within the vessels. This leads 
to incomplete necrosis, making local recurrence 
of tumours more likely.1
(3) It was capable of preserving critical structures 
(blood vessels, bile ducts, urethra, and 
nerves) within the zone of ablation. Maor 
et al8 performed an experiment by applying 
IRE directly onto the carotid arteries of six 
rats. All rats survived with no apparent side-
effects. Carotid arteries remained intact 
with no evidence of aneurysm, thrombus, or 
necrosis 28 days later. Histologically, there 
was a statistically significant decrease in mean 
vascular smooth muscle cell density (24 ± 11 
vs 139 ± 14; P<0.001) but with no apparent 
damage to extracellular matrix components 
and structure. This may explain why critical 
structures appear to be preserved with this 
new technology.
Clinical efficacy of irreversible 
electroporation on human liver 
tumours 
To date, four published case series9-12 have evaluated 
the safety and efficacy of IRE on human liver 
tumours. All of them adopted the NanoKnife system 
(AngioDynamics, New York, US), which consists 
of a footswitch, a control panel with a screen 
and a cardiac synchroniser, and a direct current 
generator connected with unipolar or bipolar needle 
electrodes. The number and placement of electrodes 
are determined by the size of the target tumour. The 
current, the applied voltage, and duration of ablation 
can be varied according to tumour characteristics. 
The procedure can be performed via percutaneous, 
laparoscopic, or open surgical approaches.9-11 
 The Table9-12 illustrates the efficacy and 
postoperative outcomes after IRE in various case 
series. The complete response rate ranged from 
72% to 100%,9-12 except in Thomson et al’s study9 
in which the complete response rate was only 50% 
for colorectal liver metastasis. That study also 
demonstrated lack of significant tumour response 
when the size of the liver metastatic lesion was larger 
#  Irreversible electroporation for liver tumour  # 
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than 5 cm.
 In Cannon et al’s study,10 however, the complete 
response rates were the same for hepatocellular 
carcinoma (HCC) and colorectal liver metastasis. 
The lower complete response rate in Thomson et al’s 
study9 could be partially attributed to the inclusion 
of larger-size tumours and greater use of the 
percutaneous approach. Consistent with Thomson 
et al’s study,9 they also showed a trend towards 
higher recurrence rates for tumours exceeding 4 cm 
in diameter.  
 The longest follow-up among these studies 
was 12 months, which was in Cannon et al’s study,10 
by which time the local recurrence rate was about 
40% for both HCC and colorectal liver metastases. 
To date, no randomised controlled trial comparing 
the efficacy of IRE and other ablation modalities 
has been published. The latest quoted figures for 
recurrence rates are approximately 2% to 15% 2 
years after radiofrequency ablation, and 11% to 35% 
2 years after percutaneous ethanol injection.13 
 The complete response rate of liver tumour to 
IRE looked promising, but a 40% local recurrence 
rate after 1 year was too high to justify its use as first-
line treatment. Moreover, tumour size seems to be 
an important consideration affecting the outcome. 
The inclusion of large tumours may have contributed 
to the high local recurrence rate in Cannon et al’s 
study.10 More prospective studies are warranted to 
define standard selection criteria in order to achieve 
satisfactory outcomes.
Adverse effects of irreversible 
electroporation
Like any other local ablative therapy, IRE is also 
associated with a few other adverse effects, be they 
general or procedure-related.
General intra-operative complications
As with all operations, IRE carries the risk of general 
anaesthesia9 and positional neuropraxia.14 In two 
retrospective studies, such effects occurred in an 
isolated number of patients but were transient and 
self-limiting, and resolved without any long-term 
disability.9,14
Specific intra-operative complications
One of the specific complications related to IRE is 
unintended injury to other organs and structures 
during manipulation of the electrodes. One instance 
of pneumothorax due to direct injury caused by 
an electrode was reported by Thomson et al.9 That 
pneumothorax resolved spontaneously and did not 
result in a delayed discharge. The same authors9 
reported another instance of direct damage by an 
instrument due to an unplanned tip insertion during 
an attempt to treat a renal tumour. That particular 
patient had transient acute hypotension, and 
subsequent mild hypotension for a further 2 months.
 Cardiac arrhythmia is a potential life-
threatening complication associated with IRE, which 
is presumed due to application of a large current close 
to the heart, especially for liver tumours situated 
below the right hemidiaphragm. Thomson et al9 and 
Ball et al14 reported cases of ventricular bigeminy, 
ventricular tachycardia, and atrial fibrillation during 
the procedure, in which a drop in blood pressure was 
associated with the arrhythmia. Furthermore, IRE 
has been incorporated with electrocardiographic 
synchronisation, rendering the possibility of intra-
operative arrhythmia less common. Although none 
of the studies reported mortality due to cardiac 
arrhythmia, this potentially devastating effect should 
not be ignored.
 In addition to cardiac arrhythmia, discharges 
from the electrode could cause muscle stimulation. 
In one case, insufficient muscle relaxant was used, 
resulting in an upper body contraction similar to 
what ensues during a grand mal seizure.14 Hence, 
IRE treatment should be performed under general 
anaesthesia with deep neuromuscular blockade, in 
order to prevent excessive body movement during 
treatment. 
 Since IRE involves the disruption of the cellular 
membrane, it results in the release of intracellular 
contents whenever tumour cells are electroporated. 
Ball et al14 reported four instances of hyperkalaemia in 
21 patients treated with IRE, but without significant 
sequelae. Early postoperative arterial blood gas 
sampling and electrocardiographic monitoring 
during the procedure may help to prevent the lethal 
TABLE.  Clinical efficacy of irreversible electroporation for liver tumours
Study Year No. of 
patients
Mean tumour size 
(range) [cm]
Complete ablation 
rate (%)
Morbidity rate 
(%)
Follow-up 
(months)
Recurrence 
rate (%)
Thomson et al9 2011 38 (1.0-5.0) 83.3 (HCC)
50.0 (CRM)
14.5 N/A N/A
Cannon et al10 2013 44 (2.1-2.7) 100 10 (90 Days) N/A 40.5 (1 Year)
Kingham et al11 2012 28 1 (0.5-5.0) N/A 3 6 5.7 (6 Months)
Cheung et al12 2013 11 2.4 (1.0-6.1) 72 36.3 18 0
Abbreviations: CRM = colorectal liver metastasis; HCC = hepatocellular carcinoma; N/A = not available
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consequence of severe hyperkalaemia. 
 Premature termination of the procedure for 
technical reasons has also been reported, but detailed 
explanations were not given.11 This complication 
subjects patients to further IRE treatments, but 
under more controlled conditions.
Postoperative complications
The postoperative complications of IRE have been 
reported in several studies. Postoperative pain was 
of primary concern for most of the operations. 
About half of the patients who underwent IRE 
had some degree of postoperative pain but those 
treated with either IRE or radiofrequency ablation 
reported similar pain scores.15 Notably, there have 
been no reported instance of vascular or biliary 
complications after IRE for periductal tumours or 
tumours abutting major vessels. This means that 
for tumours in difficult locations, it is a promising 
local ablative treatment modality compared with 
other local ablative therapies. Besides, hitherto there 
has not been any mortality directly related to IRE. 
One study reported that the mortality rate at 30 
days was 0%.9 However, another study available in 
abstract form reported one fatality 1 month after the 
operation, though no other details were provided.16 
As of 2012, IRE has been performed 158 times in 
106 patients with liver tumours, with no attributed 
mortality.7 At the time of writing, a prospective 
multicentre phase II study on the efficacy and safety 
profile of the NanoKnife System (AngioDynamics) 
for early-stage HCC has just been completed and the 
outcome of this study is eagerly awaited.
Conclusion
The tumour ablative effect of IRE appears promising. 
In particular, it seems effective for small tumours 
(<3 cm), periductal tumours, and tumours abutting 
major hepatic vessels, where conventional local 
ablative treatments for such difficult tumour 
locations could be risky and less effective.  
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